Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We found that although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of established tumors, this combination compromised anti-tumor immunity in the low tumor burden (LTB) state in pre-clinical models as well as in melanoma patients.
|
30737146 |
2019 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma.
|
31150505 |
2019 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thus, high ADCC anti-CTLA-4 mAb is able to selectively deplete effector Treg cells and evoke tumor immunity depending on the CTLA-4-expressing status of effector CD8<sup>+</sup> T cells.
|
30587582 |
2019 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Targeting immune checkpoint molecules such as programmed cell death-1 (PD-1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) reinvigorates anti-tumor immunity by restoring exhausted T cells.
|
31171886 |
2019 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity.
|
31405808 |
2019 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Inhibitors of CTLA-4 and PD-1/PD-L1 pathway can unleash anti-tumor immunity and mediate cancer regressions.
|
28403786 |
2018 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Monoclonal antibodies against the immune checkpoints cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) can restore an efficient and durable anti-tumor immunity, even following treatment discontinuation.
|
30097888 |
2018 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CTLA-4 and PD-1 are the representative examples, and their blockade by therapeutic antibodies leads to enhanced anti-tumor immunity with durable clinical responses, but only in a minority of patients.
|
30250471 |
2018 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Requirement of Treg-intrinsic CTLA4/PKCη signaling pathway for suppressing tumor immunity.
|
29212947 |
2017 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.
|
28646041 |
2017 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Oncolytic herpes simplex virus (oHSV) selectively replicates in cancer cells while inducing anti-tumor immunity. oHSV G47Δ expressing murine IL-12 (G47Δ-mIL12), antibodies to immune checkpoints (CTLA-4, PD-1, PD-L1), or dual combinations modestly extended survival of a mouse glioma model.
|
28810147 |
2017 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<b>Purpose:</b> Ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated protein-4 interactions, enhances T-cell activation and promotes tumor immunity.
|
28655793 |
2017 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The blockade of CTLA-4 mediated immune inhibitory checkpoint has been associated with enhanced anti-tumor immunity.
|
28888577 |
2017 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The discovery that antibody blockade of the T cell co-inhibitory receptor cytotoxic T lymphocyte-associated protein 4 (CTLA-4) can restore tumor immunity against many murine transplantable tumors leading to complete rejection of established cancer forever changed the field of immunotherapy.
|
25555570 |
2015 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Importantly, blocking coinhibitory molecules using antibodies specific for CTLA-4 and PD-1 enhances tumor immunity in a subset of patients.
|
25527357 |
2015 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The enhanced anti-tumor immunity in response to the CD25 depletion or CTLA-4 blockade was only seen in the immunogenic TRAMP-PSA tumor model, whereas the effect was completely absent in mice bearing poorly immunogenic TRAMP-C1 tumors.
|
25111463 |
2014 |
Tumor Immunity
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
More recently, regulation of tumor immunity through CTLA4 and PD1/L1 has emerged as a promising field in NSCLC management.
|
24192124 |
2013 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We hypothesized that local delivery of anti-CTLA-4 and anti-GITR mAbs to the sites where T cells and tumor antigen-loaded DC vaccines interact would enhance the induction of anti-tumor immunity while avoiding autoimmunity.
|
22028176 |
2011 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These findings suggest that increased sCTLA4 may contribute in CTLA4-induced suppression of tumor immunity and provide explanations for the widely reported association of CTLA4 gene with cancer.
|
20482250 |
2010 |
Tumor Immunity
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
|
16037385 |
2005 |